Background
Researchers have indicated that they want access to novel target antibodies quickly to aid in their research. IMGENEX is pleased to be able to offer researchers access to cutting-edge products that are still in the process of characterization/validation. IMGENEX’s ‘IMX’ antibody line is shown by ELISA to bind to the peptide used as immunogen. Investigators should empirically determine the suitability of the antibody, including optimal dilutions, for other applications of interest.
 |
We cannot guarantee that the yet-to-be-fully validated antibody will work in any application other than in an ELISA against the peptide used as immunogen and therefore cannot offer a refund if the antibody does not work in your application. |
|
The antibody is offered at a lower price compared to a more highly validated antibody. |
|
We are not able to provide the immunogen for the antibodies, but do provide the amino acid sequence. |
These antibodies are not fully validated and we appreciate your feedback. Customer feedback is used to help generate testing methodologies which can lead to further product validation or withdrawal.
Caudal type homeo box transcription factor 4 (CDX4) is a member of the caudal-type homeobox genes which are candidates for directing tissue and organ development and differentiation. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. CDX4 is located within the minimal region assigned to XIC in humans and furthermore, CDX4 is the closest known gene to XIST in both mouse and human. Unlike Xist, CDX4 appears to be normally X-inactivated in mice and it is not clear yet whether the location of this gene within the XIC region is of any significance in X-inactivation. |
